Skip to content

Research on the Neural Mechanism and Diagnosis and Treatment Model of Amblyopia and Strabismus Based on Multimodal Database

Research on the Neural Mechanism and Diagnosis and Treatment Model of Amblyopia and Strabismus Based on Multimodal Database

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098177
Enrollment
Unknown
Registered
2025-03-04
Start date
2024-08-16
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Strabismus, amblyopia

Interventions

Acute Acquired Concomitant Esotropia:None
Healthy control:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion Criteria for Amblyopia Patients: age 12-40 years; no gender restriction; diagnoses of strabismic amblyopia, anisometropic amblyopia, refractive amblyopia, and deprivation amblyopia; participants must be able to comply with treatment protocols and attend follow-up visits; participants must be capable of understanding and cooperating with behavioral, EEG, MRI, and eye movement measurements. 2. Inclusion Criteria for Strabismus Patients: age 12-40 years; diagnoses of congenital esotropia, acute functional esotropia, congenital exotropia, and intermittent exotropia; participants must be able to comply with treatment protocols and attend follow-up visits; participants must be capable of understanding and cooperating with behavioral, EEG, MRI, and eye movement measurements. 3.Inclusion Criteria for Normal Controls: age 12-40 years; best corrected visual acuity of 0.9 or better in both eyes; refractive error between -6.00D and +6.00D (inclusive), with astigmatism less than 2.00D; interocular spherical refractive difference less than 1.50D, and interocular cylindrical refractive difference less than 1.00D; regular use of corrective eyewear; normal ocular alignment with horizontal near and distant heterophoria between -10 and +5 PD (inclusive), no vertical heterophoria; normal eye movements; stereopsis (random dot and contour stereotests) <=60"; normal visual function on the synoptophore with simultaneous vision, fusion, and stereopsis present; ability to attend follow-up visits and understand and cooperate with behavioral, EEG, MRI, and eye movement measurements.

Exclusion criteria

Exclusion criteria: 1. Exclusion Criteria for Amblyopia Patients: ocular organic lesions; nystagmus; history of intraocular surgery or refractive surgery; any ocular complications diagnosed within the past 7 months that may impair vision; Down syndrome or cerebral palsy; severe developmental delay as determined by the investigator, such as language or reading disabilities; history of head trauma with associated psychiatric or neurological disorders; metabolic diseases such as diabetes or hyperthyroidism; systemic diseases involving cardiovascular, liver, kidney, or pulmonary organs; history of alcohol or drug abuse; contraindications for MRI, such as claustrophobia; any condition that, in the investigator's judgment, may compromise the safety or well-being of the participant and thus deem them unsuitable for inclusion in the study. 2.Exclusion Criteria for Strabismus Patients: same as the exclusion criteria for amblyopia patients. 3.Exclusion Criteria for Normal Controls: same as the exclusion criteria for amblyopia patients.

Design outcomes

Primary

MeasureTime frame
Visual acuity;Neuroimaging Data;Eye tracking data;Electroencephalogram;Deviation;

Secondary

MeasureTime frame
Stereopsis;Adult Strabismus-20;The Amblyopia and Strabismus Questionnaire;National Eye Institute Visual Functioning Questionnaire 25;Self-Rating Depression Scale;Self-Rating Anxiety Scale;

Countries

China

Contacts

Public ContactLiu Longqian

West China Hospital, Sichuan University

liulq@scu.edu.cn+86 189 8060 1759

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026